secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-036816
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026
--------------------------------------------------------------------------------

- FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.
- Cash $116.7M at Dec 31, 2023; recent $40M public offering and CAR T licensing deals add ~$50M.
- Completed licensing deals with Imugene, TG Therapeutics, and Caribou; total upfront/near-term ~$50M.
- PBGENE-HBV IND/CTA submission planned in 2024; PBGENE-PMM submission in 2025.
- Net loss per diluted share $(15.96) vs $(38.10) in FY 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/0000950170-24-036816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/dtil-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer